Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies.
Sign Up to like & getrecommendations! Published in 2019 at "Lung cancer"
DOI: 10.1016/j.lungcan.2019.09.015
Abstract: OBJECTIVES There are limited treatment options for patients with thymic malignancies. Here we present data supporting treatment with single agent amrubicin, a third generation anthracycline and topoisomerase II inhibitor. MATERIALS AND METHODS This was a… read more here.
Keywords: agent; single agent; thymic malignancies; amrubicin patients ... See more keywords